IPHAInnate PharmaSigning up patients
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Non Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 70 (planned)
- Started
- Jun 23, 2023
- Main results expected
- Jun 2027
- Fully finished
- Jun 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Pathological Complete Response (pCR)
Measured over: 16 weeks after the first dose of study intervention.
Adverse events (AEs) and serious adverse events (SAEs)
Measured over: Until Day 90 after the last dose of study interventions.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05742607 · record last updated 2026-06-17 · checked 2026-11-09 15:42 UTC